Safety analysis of Intensity-modulated radiation therapy of glioblastoma with simultaneous integrated boost technique
Wang Zheng*,Jiang Wei,Pang Qingsong,Wang Ping
*Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin 300060,China
Abstract：Objective To investigate clinical efficacy of simultaneous integrate boost for glioblastoma with intensity-modulated radiotherapy (SIB-IMRT). Methods A total of 46 patients with glioblastoma who underwents SIB-IMRT from January 2013 to August 2014,were retrospectively analyzed. Toxicity after completion of SIB-IMRT were assessed. Kaplan-Meier method was used to analyze survival and progression-free survival. Multivariate analyses were performed to determine significant prognostic factors. Results There was no patients delayed by more than grade 3 radiation toxicity. The median overall survival and 1-year survival rates was 69 weeks and 73%,respectively. The progression free survival and 1-year progression-free survival rate were 43 weeks and 39%,respectively. The pattern of failure was identical (9 Local, 7 distant and 0 marginal recurrence). Multivariate analyses show that temozolomide concurrent chemoradiotherapy were independent factors correlated to prognosis. Conclusions The preliminary results demonstrate that SIB-IMRT for glioblastoma appear to be effective and safe. With the limted number of patients in this group,SIB-IMRT could be used for treating glioblastoma with caution,which deserves further study.
Wang Zheng*,Jiang Wei,Pang Qingsong et al. Safety analysis of Intensity-modulated radiation therapy of glioblastoma with simultaneous integrated boost technique[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 431-433.
[1] Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma[J]. J Clin Oncol,2009,27(5):740-745.DOI:10.1200/jco.2008.16.3055. [2] Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J]. Clin Cancer Res,2007,13(4):1253-1259.DOI:10.1158/1078-0432.CCR-06-2309. [3] Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme[J]. J Clin Oncol,2007,25(30):4722-4729.DOI:10.1200/JCO.2007.12.2440. [4] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst,2000,92(3):205-216.DOI:10.1093/jnci/92.3.205. [5] Walker MD, Alexander E Jr, Hunt WE,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial[J].J Neurosurg,1978,49(3):333-343. [6] Iuchi T, Hatano K, Narita Y, et al. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT[J].Int J Radiat Oncol Biol Phys,2006,64(5):1317-1324. [7] Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme[J]. Can J Neurol Sci,2010,37(1):36-42. [8] Souhami L, Seiferheld W, Brachman D,et al. Randomized comparison of stereotactic adiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme:report of radiation rherapy oncology group 93-05 protocol[J].Int J Radiat Oncol Biol Phys,2004,60(3):853-560. [9] Chang EL, Akyurek S, Avalos T,et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma[J].Int J Radiat Oncol Biol Phys,2007,68(1):144-150. [10] Halperin EC, Bentel G, Heinz ER, et al. Radiation therapy treatment planning in supratentorial glioblastoma multiforme:An analysis based on post mortem topographic anatomy with CT correlations[J]. Int J Radiat Oncol Biol Phys,1989,17(6):1347-1350. [11] Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma:correlation with MGMT promoter methylation status[J]. J Clin Oncol,2009,27(8):1275-1279.DOI:10.1200/JCO.2008.19.4969.
2015, Vol. 24 
